Optimized hGBA1-mRNA Enhances GCase Function in Gaucher Models

Study Background and Research Question

Gaucher disease (GD) is a rare autosomal-recessive lysosomal storage disorder caused by mutations in the GBA1 gene, leading to deficient β-glucocerebrosidase (GCase) activity. The enzymatic shortfall results in lysosomal accumulation of glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph), primarily within macrophages, forming characteristic Gaucher cells. Clinical manifestations range from hepatosplenomegaly and anemia to severe neurological involvement, depending on disease subtype. Standard treatments include enzyme replacement therapy (ERT) and substrate reduction therapy (SRT). While ERT supplies functional GCase, it is constrained by high cost, frequent infusions, immunogenic risks, and limited efficacy in addressing neurological symptoms due to the blood-brain barrier (reference study). These challenges highlight the need for innovative approaches that can achieve sustained lysosomal enzyme restoration and offer broader tissue targeting.

Key Innovation from the Reference Study

The reference study introduces a rationally engineered human GBA1 mRNA platform designed to maximize GCase expression and stability for therapeutic application in GD. Unlike recombinant protein administration, this strategy leverages the cell's own translational machinery to synthesize GCase, potentially enabling more authentic post-translational modifications and trafficking. The mRNA constructs were systematically optimized by altering untranslated regions (UTRs), codon usage, and poly(A) tail length, resulting in >6-fold increased GCase activity compared to less efficient variants in cell models (reference study). The optimized mRNA was delivered via lipid nanoparticles (LNPs), a clinically validated platform for mRNA therapies, supporting robust delivery and expression in multiple tissues.

Methods and Experimental Design Insights

The research team employed a multi-pronged experimental design:

• Systematic alteration of 5′ and 3′ UTRs, codon optimization, and poly(A) tail length to enhance mRNA translation and stability.
• Transfection of HEK293T and RAW264.7 cell lines with each mRNA variant, followed by assessment of GCase activity and protein half-life.
• Generation of GBA1-knockout (KO) HEK293T cells to evaluate rescue of lysosomal function and substrate clearance.
• In vivo administration of LNP-encapsulated hGBA1-mRNA in wild-type FVB mice, with subsequent quantification of GCase activity in liver and spleen.
• Assessment of lysosomal targeting through immunolabeling and restoration of normal cellular morphology.

These approaches enabled the dissection of both the biochemical and functional efficacy of the optimized mRNA constructs, providing a robust preclinical evaluation pipeline.

Core Findings and Why They Matter

The study's main findings can be summarized as follows:

• Enhanced GCase Expression and Activity: Optimized mRNA constructs achieved over sixfold higher GCase activity at 24 hours post-transfection relative to the least efficient design. The average half-life of GCase expression surpassed 54 hours, indicating improved intracellular stability (reference study).
• Lysosomal Targeting and Functional Rescue: The mRNA-encoded GCase correctly localized to lysosomes, restored normal organelle morphology, and reduced GlcCer accumulation in GBA1-KO cells. This directly addresses the cellular defect underlying GD and demonstrates the platform’s biological relevance.
• In Vivo Efficacy: A single intravenous administration of hGBA1-mRNA-LNP resulted in detectable GCase activity in mouse liver and spleen within 72 hours, demonstrating the potential for systemic delivery and organ-targeted enzyme restoration.
• Therapeutic Implications: These results suggest that mRNA-LNP therapy could overcome key limitations of ERT, including short protein half-life, immunogenicity, and restricted biodistribution, potentially providing a more sustainable and flexible treatment option.

Comparison with Existing Internal Articles

Several recent articles corroborate and expand on these findings:

• The internal review "Optimized hGBA1-mRNA Restores Lysosomal Function in Gaucher Models" emphasizes the robust enhancement in lysosomal targeting and functional correction achieved through engineered hGBA1 mRNA, supporting the reference study's conclusions on mRNA-LNP as a next-generation therapy for lysosomal storage disorders.
• "4-Methylumbelliferyl-β-D-Glucopyranoside in Lysosomal Enzyme Assays" highlights the essential role of 4-MUG as a fluorogenic substrate in accurately quantifying β-glucocerebrosidase activity. This analytical approach underpins the experimental workflow in both the reference and internal articles, enabling sensitive evaluation of therapeutic efficacy and enzyme kinetics in cellular and animal models.
• Additional reports, such as "Optimized GBA1-mRNA Restores GCase Activity for Gaucher Therapy", reinforce the reproducibility of these findings across different model systems and experimental conditions, underscoring the growing consensus for mRNA therapeutics in GD research.

Limitations and Transferability

While the study provides compelling preclinical evidence, several limitations should be considered:

• All in vivo data were generated in wild-type mouse models with intact GBA1, rather than true GD models. Thus, therapeutic efficacy and biodistribution in the context of chronic substrate accumulation and immune dysfunction remain to be validated.
• Although lysosomal targeting and enzyme activity were confirmed in vitro and in select tissues in vivo, comprehensive studies on tissue-specific delivery, especially to the central nervous system, are lacking.
• Potential immunogenicity of repeated mRNA-LNP administration and the long-term durability of therapeutic benefit need further investigation in disease-relevant models.

Given these considerations, the platform demonstrates strong translational promise but requires additional optimization and validation for clinical application. The experimental workflow, particularly the β-glucocerebrosidase activity assay using fluorogenic substrates, is broadly transferable to other lysosomal storage disorder research and preclinical drug development.

Protocol Parameters

• hGBA1-mRNA Transfection: Transfect HEK293T or RAW264.7 cells with 0.5–1 μg mRNA per 1 × 10⁵ cells; assess GCase activity 24–72 h post-transfection.
• Lipid Nanoparticle (LNP) Delivery: Use intravenous injection of hGBA1-mRNA-LNPs in mice at 0.5–1 mg/kg; harvest tissues for enzyme analysis 72 h post-administration.
• β-Glucocerebrosidase Activity Assay: Employ 4-Methylumbelliferyl-β-D-Glucopyranoside (4-MUG) at 0.1–1 mM in acetate buffer (pH 5.5); monitor fluorescence (excitation: 355–365 nm; emission: 445–454 nm) after incubation at 37°C for 30–60 min.
• Sample Preparation: For cell lysates, use 0.2–1 mg total protein per reaction; for tissue, homogenize and normalize protein input accordingly.
• Storage: Store 4-MUG substrate at –20°C, minimizing freeze-thaw cycles to maintain stability, as recommended by product information.

Research Support Resources

For researchers seeking to replicate or extend these workflows, 4-Methylumbelliferyl-β-D-Glucopyranoside (4-MUG, SKU C3426) is widely used for quantitative β-glucosidase and β-glucocerebrosidase activity assays in both cell-based and in vitro systems. This substrate's robust fluorescence properties and compatibility with high-throughput formats make it an essential tool for lysosomal enzyme activity studies. APExBIO provides high-purity 4-MUG suitable for these applications, with detailed solubility and storage guidelines to ensure assay reproducibility and reliability. Integrating such standardized reagents is critical for advancing translational research in glycosphingolipid metabolism and mRNA-based therapeutic development.